Related Experiment Videos
Nonthrombolytic intervention in acute myocardial infarction
1Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts 02115.
The American Journal of Cardiology
|July 18, 1989
Summary
Beta blockers administered early after acute myocardial infarction significantly reduce short-term and long-term mortality. Esmolol offers a safe option for patients with contraindications, aiding in early treatment and screening for long-acting beta blockers.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Thrombolytic therapy is not suitable for all acute myocardial infarction patients.
- Beta blockers are established treatments for myocardial infarction.
Purpose of the Study:
- To evaluate the efficacy of early beta blocker administration post-acute myocardial infarction.
- To assess the utility of esmolol in managing patients with contraindications to beta blockers.
Main Methods:
- Administration of beta blockers within 24 hours of coronary care unit admission.
- Use of esmolol, a short-acting beta 1-adrenergic receptor blocker, for early therapy and screening.
- Transition to long-acting oral beta blockers for tolerated esmolol infusions.
Main Results:
- Early beta blocker administration reduced 7-day morbidity and mortality by approximately 15%.
- Maintenance oral beta blocker therapy reduced 3-year mortality by about 25%.
- Esmolol allowed early beta-blocker therapy in patients with relative contraindications and facilitated screening.
Conclusions:
- Early beta blocker therapy is crucial for reducing mortality after acute myocardial infarction.
- Esmolol serves as a valuable tool for initiating beta blocker therapy in select high-risk patients and for screening purposes.